Supplementary Material for: Hedgehog pathway- and PD-1 inhibitors for advanced basal cell carcinoma

Here we report in detail the management of three complex advanced BCC (aBCC) cases treated with nivolumab and pembrolizumab after vismodegib failure. All patients were treated with PD-1 inhibitors before cemiplimab was approved by the FDA and EMA. On all tumors next generation DNA sequencing in the Center for Personalized Cancer Treatment-02 (CPCT-02) study was performed and subsequently patients were included in the Drug Rediscovery Protocol (DRUP) trial, in which treatment was started with commercially available targeted anti-cancer drugs based on the molecular tumor profile.

本研究详细报告了3例经维莫德吉（vismodegib）治疗失败后，采用纳武利尤单抗（nivolumab）与帕博利珠单抗（pembrolizumab）治疗的复杂性晚期基底细胞癌（Basal Cell Carcinoma, BCC）病例的诊疗经过。所有患者均在塞瑞利尤单抗（cemiplimab）获美国食品药品监督管理局（FDA）与欧洲药品管理局（EMA）批准前接受了PD-1抑制剂（PD-1 inhibitors）治疗。所有肿瘤样本均于个性化癌症治疗中心-02（Center for Personalized Cancer Treatment-02, CPCT-02）研究中完成下一代DNA测序，随后患者被纳入药物再发现方案（Drug Rediscovery Protocol, DRUP）试验，该试验依据肿瘤分子谱为患者选用已上市的靶向抗肿瘤药物开展治疗。